Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression
Arthritis & Rheumatology · 01.07.2026
DOI: 10.1002/art.70251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 01.07.2026. Verfasst von Sacha E Silva-Saffar und 6 weiteren Autor:innen. Beteiligte Einrichtung: GenHotel - European Research Laboratory for Rheumatoid Arthritis, Université Évry Paris-Saclay, Evry-Courcourconnes, France. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Association Française du Syndrome de Gougerot-Sjögren et des syndromes secs, Bristol-Myers Squibb Foundation, French Society of rheumatology.
Abstract (Originalsprache)
Objective
Sjögren disease (SjD) is a heterogeneous autoimmune disease. We aimed to investigate blood transcriptomic signatures and disease progression among three recently defined clusters of patients with SjD: (1) B cell active disease with low symptom burden (BALS), (2) high systemic activity (HSA), and (3) low systemic activity with high symptom burden (LSAHS).
Methods
We analyzed transcriptomic data from the ASSESS cohort (GSE140161; n = 351). Patients were classified into the three clusters previously described. Within BALS, an evolutive subgroup was defined based on need for new immunosuppressants and/or occurrence of lymphoma (BALS subgroup of patients with progressive/evolving disease [BALS_Evol]). Differential expression analysis and Gene Set Enrichment Analysis were performed to evaluate subgroup‐specific signatures and biologic pathways.
Results
Both BALS and HSA displayed robust types I/II interferon (IFN)‐stimulated gene up‐regulation compared to LSAHS. BALS exhibited stronger IFN activity and inflammatory signaling than HSA, particularly in the evolutive subgroup (BALS_Evol). This subgroup showed enrichment of IFNα/γ, tumor necrosis factor α, interleukin‐6, complement activation, and mechanistic target of rapamycin (mTOR) complex 1 pathways, indicating a hyperinflammatory and dysregulated immune state linked to disease progression. In contrast, compared with BALS, the HSA cluster displayed attenuated IFN and KRAS pathway activity, coupled with activation of MYC, mTOR, and oxidative phosphorylation, suggesting a molecular shift toward proliferation and metabolism that may promote systemic disease evolution.
Conclusion
IFN signaling is a hallmark of both HSA and BALS clusters. In BALS, it may drive early disease progression, which can be replaced later by proliferative pathways leading to an HSA. These findings pave the way for new hypotheses regarding the mechanisms driving disease progression in SjD. image
Autor:innen und Institutionen
- GenHotel - European Research Laboratory for Rheumatoid Arthritis, Université Évry Paris-Saclay, Evry-Courcourconnes, France.
- Paris-Saclay University, Inserm, Commissariat à l'Energie Atomique, Immune diseases, microbiology and innovative therapies (IDMIT/UMRS1184), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
- Department of Immuno-Rheumatology, Hôpital Bicêtre, Université Paris-Saclay, Assistance Publique - Hôpitaux de Paris, Paris, France.
- Centre for Research in Epidemiology and Statistics, Université Paris Cité and Université Sorbonne Paris Nord, Inserm, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement, Paris, France.
- Department of Internal Medicine, Hôpital Beaujon, Université Paris Cité, Assistance Publique - Hôpitaux de Paris, Clichy, France.
- Service de Rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
ORCID-Profile: Yann Nguyen, Jacques-Eric Gottenberg, Gaetane Nocturne
Förderung
- Association Française du Syndrome de Gougerot-Sjögren et des syndromes secs
- Bristol-Myers Squibb Foundation
- French Society of rheumatology
- Programme Hospitalier de Recherche Clinique
- Innovative Medicines Initiative 2 Joint
Zitieren
APA
Silva-Saffar, S. E., Nguyen, Y., Seror, R., Gottenberg, J. E., Niarakis, A., Mariette, X., & Nocturne, G. (2026). Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression. Arthritis & Rheumatology. https://doi.org/10.1002/art.70251
Vancouver
Silva-Saffar SE, Nguyen Y, Seror R, Gottenberg JE, Niarakis A, Mariette X, et al. Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression. Arthritis & Rheumatology. 2026. doi:10.1002/art.70251
BibTeX
@article{SilvaSaffar2026,
author = {Silva-Saffar, Sacha E and Nguyen, Yann and Seror, Raphaèle and Gottenberg, Jacques-Eric and Niarakis, Anna and Mariette, Xavier and Nocturne, Gaetane},
title = {Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70251}
}
EUVIMED